Thalia Therapeutics PLC
LLSE:THAT0.60
GBX
0.00
(0.00%)
Thalia Therapeutics PLC
LSE:THAT
(London Stock Exchange)
Recent
price
0.60
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
GBP
•
in mil. unless spec.Working Capital
GBP
•
in mil. unless spec.Growth Rates
GBP
•
in mil. unless spec.Semi-annual Revenue
GBP
•
in mil. unless spec.Semi-annual Earnings Per Share
GBP
•
in mil. unless spec.Semi-annual Dividends Per Share
GBP
•
in mil. unless spec.- Similar Companies
- Business
- Thalia Therapeutics Plc, an AIM-listed biopharmaceutical company, develops RNA delivery technologies and RNA-based therapeutics with a focus on oncology and cardiovascular disease, leveraging its Nuvec and LipTide platforms to improve intracellular delivery of nucleic acids, vaccines, and related therapeutics. The company operates primarily through its UK subsidiaries, including N4 Pharma UK Limited and Nanogenics Limited, and targets licensing opportunities with pharmaceutical and biotech partners for preclinical and early clinical programs. Main products and services - Nuvec delivery system: amorphous silica nanoparticle platform designed to enhance intracellular delivery and potency of RNA, DNA, and siRNA therapies; surface-engineered to trap and protect payloads and enable targeted delivery; suitable for nucleic acid therapeutics development and potential licensing for partner programs. - LipTide delivery system: lipid-peptide delivery platform that mimics viral delivery; combines peptide-based payload binding with lipid-mediated endosomal release to facilitate efficient RNA delivery into cells; pursued for targeted RNA therapeutics in oncology and cardiovascular indications. - RNA therapeutics development: in-house and partnered programs focusing on delivering siRNA and other RNA modalities; pipelines emphasize long-duration, multi-target approaches for cardiovascular and cancer indications. - Licensing and collaboration services: offers Nuvec and LipTide-based platforms to pharmaceutical and biotech partners for research, development, and commercialization of nucleic acid products, including opportunity for co-development or out-licensing of assets. Latest major company changes - Strategic evolution and rebranding toward Thalia Therapeutics to reflect expanded RNA-based therapeutic focus, with emphasis on cardiovascular and oncologic applications and platform-driven asset expansion. - Appointment and leadership changes signaling strategic shift toward RNA delivery and therapeutics, including CEO discussions and governance updates aligned with the new Thalia Therapeutics strategy. - Strategic updates to broaden the asset portfolio and explore acquisitions or collaborations to accelerate development of RNA-based programs, particularly those leveraging Nuvec and LipTide delivery systems. - Incorporation of new product development initiatives targeting high-growth, high-value markets in cardiovascular disease (notably siRNA approaches) and oncology, with potential licensing of Nuvec/LipTide assets to external partners. Additional context - Industry and segments: biotechnology; RNA therapeutics; drug delivery platforms; nanoparticle-based delivery; targeted RNA therapies. - Target markets and customers: pharmaceutical and biotech partners seeking novel delivery solutions for nucleic acid therapeutics; potential licensing for preclinical and clinical-stage programs; healthcare stakeholders interested in reducing cardiovascular risk and cancer burden through RNA-based interventions. - Geographic operations: United Kingdom-based upstream research and development; activities and partnerships with global pharmaceutical collaborators; regulatory and potential commercialization paths across Europe, the United States, and other regions. - Founding year and headquarters: established in the UK with headquarters in London and operations centered in the UK through its subsidiaries N4 Pharma UK Limited and Nanogenics Limited; rebranding to Thalia Therapeutics reflects strategic pivot while maintaining UK governance. - Subsidiaries/parent relationships: includes N4 Pharma UK Limited and Nanogenics Limited as subsidiary entities under the Thalia Therapeutics corporate structure; parent company relationships align with legacy N4 Pharma assets and new Thalia Therapeutics initiatives. - Notable platforms: Nuvec for intracellular RNA delivery using silica nanoparticles; LipTide for lipid-peptide-based RNA delivery, enabling targeted uptake and endosomal escape.